Unity Biotechnology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UBX research report →
Companyunitybiotechnology.com
Unity Biotechnology, Inc. , a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
- CEO
- Anirvan Ghosh
- IPO
- 2018
- Employees
- 16
- HQ
- South San Francisco, CA, US
Price Chart
Valuation
- Market Cap
- $3.44M
- P/E
- -0.21
- P/S
- 2.59
- P/B
- -16.47
- EV/EBITDA
- -1.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 36.60%
- Op Margin
- -1072.36%
- Net Margin
- -1185.39%
- ROE
- -500.62%
- ROIC
- -56.55%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-25,990,000 · 34.80%
- EPS
- $-1.54 · 42.96%
- Op Income
- $-31,171,000
- FCF YoY
- 43.76%
Performance & Tape
- 52W High
- $3.10
- 52W Low
- $0.10
- 50D MA
- $0.66
- 200D MA
- $1.23
- Beta
- 1.06
- Avg Volume
- 761.63K
Get TickerSpark's AI analysis on UBX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 27, 25 | Jalbert Craig R. | other | 0 |
| Apr 2, 25 | Nguyen Alexander Hieu | sell | 17,852 |
| Apr 2, 25 | Sullivan Lynne Marie | sell | 21,867 |
| Apr 2, 25 | Ghosh Anirvan | sell | 96,797 |
| Mar 28, 25 | Nguyen Alexander Hieu | other | 73,000 |
| Mar 28, 25 | Nguyen Alexander Hieu | other | 44,000 |
| Mar 27, 25 | Nguyen Alexander Hieu | sell | 1,954 |
| Mar 28, 25 | Sullivan Lynne Marie | other | 65,000 |
| Mar 28, 25 | Sullivan Lynne Marie | other | 106,000 |
| Mar 28, 25 | Ghosh Anirvan | other | 286,000 |
Our UBX Coverage
We haven't published any research on UBX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate UBX Report →